145 related articles for article (PubMed ID: 36853806)
1. Erythrocyte pyruvate kinase activation in red cell disorders.
Matte A; Federti E; De Franceschi L
Curr Opin Hematol; 2023 May; 30(3):93-98. PubMed ID: 36853806
[TBL] [Abstract][Full Text] [Related]
2. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder P; Fulzele K; Forsyth S; Ribadeneira MD; Guichard S; Wilker E; Marshall CG; Drake A; Fessler R; Konstantinidis DG; Seu KG; Kalfa TA
J Pharmacol Exp Ther; 2022 Mar; 380(3):210-219. PubMed ID: 35031585
[TBL] [Abstract][Full Text] [Related]
3. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
4. Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease.
Xu JZ; Vercellotti GM
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):107-113. PubMed ID: 38066891
[TBL] [Abstract][Full Text] [Related]
5. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
6. Mitapivat increases ATP and decreases oxidative stress and erythrocyte mitochondria retention in a SCD mouse model.
Quezado ZMN; Kamimura S; Smith M; Wang X; Heaven MR; Jana S; Vogel S; Zerfas P; Combs CA; Almeida LEF; Li Q; Quezado M; Horkayne-Szakaly I; Kosinski PA; Yu S; Kapadnis U; Kung C; Dang L; Wakim P; Eaton WA; Alayash AI; Thein SL
Blood Cells Mol Dis; 2022 Jul; 95():102660. PubMed ID: 35366607
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate kinase activators: targeting red cell metabolism in thalassemia.
Kuo KHM
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):114-120. PubMed ID: 38066911
[TBL] [Abstract][Full Text] [Related]
8. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Xu JZ; Conrey A; Frey I; Gwaabe E; Menapace LA; Tumburu L; Lundt M; Lequang T; Li Q; Glass K; Dunkelberger EB; Iyer V; Mangus H; Kung C; Dang L; Kosinski PA; Hawkins P; Jeffries N; Eaton WA; Lay Thein S
Blood; 2022 Nov; 140(19):2053-2062. PubMed ID: 35576529
[TBL] [Abstract][Full Text] [Related]
10. Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane.
Andres O; Loewecke F; Morbach H; Kraus S; Einsele H; Eber S; Speer CP
Br J Haematol; 2019 Nov; 187(3):386-395. PubMed ID: 31273765
[TBL] [Abstract][Full Text] [Related]
11. Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease.
D'Alessandro A; Le K; Lundt M; Li Q; Dunkelberger EB; Cellmer T; Worth AJ; Patil S; Huston C; Grier A; Dzieciatkowska M; Stephenson D; Eaton WA; Thein SL
Haematologica; 2024 Mar; ():. PubMed ID: 38450513
[TBL] [Abstract][Full Text] [Related]
12. One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.
van Dijk MJ; Rab MAE; van Oirschot BA; Bos J; Derichs C; Rijneveld AW; Cnossen MH; Nur E; Biemond BJ; Bartels M; Jans JJM; van Solinge WW; Schutgens REG; van Wijk R; van Beers EJ
Blood Adv; 2023 Dec; 7(24):7539-7550. PubMed ID: 37934880
[TBL] [Abstract][Full Text] [Related]
13. Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis.
Matte A; Wilson AB; Gevi F; Federti E; Recchiuti A; Ferri G; Brunati AM; Pagano MA; Russo R; Leboeuf C; Janin A; Timperio AM; Iolascon A; Gremese E; Dang L; Mohandas N; Brugnara C; De Franceschi L
JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37676741
[TBL] [Abstract][Full Text] [Related]
14. Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Forsyth S; Schroeder P; Geib J; Vrishabhendra L; Konstantinidis DG; LaSalvia K; Ribadeneira MD; Wu E; Kelly P; Kalfa TA
Clin Pharmacol Drug Dev; 2022 May; 11(5):654-665. PubMed ID: 35019238
[TBL] [Abstract][Full Text] [Related]
15. Hereditary disorders of the erythrocyte.
Crowley C; Necheles TF
Clin Perinatol; 1976 Mar; 3(1):161-75. PubMed ID: 782768
[No Abstract] [Full Text] [Related]
16. Ineffective erythropoiesis in sickle cell disease: new insights and future implications.
El Nemer W; Godard A; El Hoss S
Curr Opin Hematol; 2021 May; 28(3):171-176. PubMed ID: 33631786
[TBL] [Abstract][Full Text] [Related]
17. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
18. Relationship of density distribution and pyruvate kinase electrophoretic pattern of erythrocytes in sickle cell diseases and other disorders.
Oda S; Oda E; Tanaka KR
Acta Haematol; 1978; 60(4):201-9. PubMed ID: 101007
[TBL] [Abstract][Full Text] [Related]
19. [Reduced deformability of erythrocytes as a common denominator of hemolytic anemias].
Tillmann W
Wien Med Wochenschr; 1986; 136 Spec No():14-6. PubMed ID: 3548086
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency.
Song AB; Al-Samkari H
Expert Rev Hematol; 2022 Oct; 15(10):875-885. PubMed ID: 36124781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
